Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
Sage Therapeutics looks to keep up momentum with SAGE-217 in bipolar depression, while Marinus tries to catch up with an oral postpartum depression project.